Related references
Note: Only part of the references are listed.Common Genetic Variation and Antidepressant Efficacy in Major Depressive Disorder: A Meta-Analysis of Three Genome-Wide Pharmacogenetic Studies
Rudolf Uher
AMERICAN JOURNAL OF PSYCHIATRY (2013)
Epigenetic Mechanisms of Depression and Antidepressant Action
Vincent Vialou et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 53, 2013 (2013)
Proteomic and metabolomic profiling reveals time-dependent changes in hippocampal metabolism upon paroxetine treatment and biomarker candidates
Christian Webhofer et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2013)
Shared genetics among major psychiatric disorders
Alessandro Serretti et al.
LANCET (2013)
Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis
Jordan W. Smoller et al.
LANCET (2013)
Epigenetics of the Depressed Brain: Role of Histone Acetylation and Methylation
HaoSheng Sun et al.
NEUROPSYCHOPHARMACOLOGY (2013)
FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder
Katarzyna A. Ellsworth et al.
PHARMACOGENETICS AND GENOMICS (2013)
Toward Clinically Useful Neuroimaging in Depression Treatment Prognostic Utility of Subgenual Cingulate Activity for Determining Depression Outcome in Cognitive Therapy Across Studies, Scanners, and Patient Characteristics
Greg J. Siegle et al.
ARCHIVES OF GENERAL PSYCHIATRY (2012)
The economic cost of brain disorders in Europe
J. Olesen et al.
EUROPEAN JOURNAL OF NEUROLOGY (2012)
Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy
Stefano Porcelli et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2012)
Surrogate markers of treatment outcome in major depressive disorder
George I. Papakostas
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2012)
Comprehending depression through proteomics
Daniel Martins-de-Souza
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2012)
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010
Christopher J. L. Murray et al.
LANCET (2012)
Little things on which happiness depends: microRNAs as novel therapeutic targets for the treatment of anxiety and depression
R. M. O'Connor et al.
MOLECULAR PSYCHIATRY (2012)
HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity
Mitsumasa Kurita et al.
NATURE NEUROSCIENCE (2012)
MicroRNAs and depression
Sophie Mouillet-Richard et al.
NEUROBIOLOGY OF DISEASE (2012)
Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers
Keren Oved et al.
PHARMACOGENOMICS (2012)
Pharmacoproteomic investigation into antidepressant response in two mouse inbred strains
Karim Malki et al.
PROTEOMICS (2012)
Are We Getting Closer to Valid Translational Models for Major Depression?
Olivier Berton et al.
SCIENCE (2012)
Predictors of remission in depression to individual and combined treatments (PReDICT): study protocol for a randomized controlled trial
Boadie W. Dunlop et al.
TRIALS (2012)
Convergent animal and human evidence suggests the activin/inhibin pathway to be involved in antidepressant response
K. Ganea et al.
TRANSLATIONAL PSYCHIATRY (2012)
Convergent Animal and Human Evidence Suggests a Role of PPM1A Gene in Response to Antidepressants
Karim Malki et al.
BIOLOGICAL PSYCHIATRY (2011)
Pharmacogenetics of antidepressant response
Robert Keers et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2011)
The Neuronal Transporter Gene SLC6A15 Confers Risk to Major Depression
Martin A. Kohli et al.
NEURON (2011)
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Dennis Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
MicroRNA Expression Profiling Reveals MiRNA Families Regulating Specific Biological Pathways in Mouse Frontal Cortex and Hippocampus
Juuso Juhila et al.
PLOS ONE (2011)
Gene expression biomarkers of response to citalopram treatment in major depressive disorder
F. Mamdani et al.
TRANSLATIONAL PSYCHIATRY (2011)
Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept
R. Kaddurah-Daouk et al.
TRANSLATIONAL PSYCHIATRY (2011)
Personalized Medicine for Depression: Can We Match Patients With Treatments?
Gregory E. Simon et al.
AMERICAN JOURNAL OF PSYCHIATRY (2010)
Pharmacogenetics in Psychiatry - A Useful Clinical Tool or Wishful Thinking for the Future?
J. Kirchheiner et al.
CURRENT PHARMACEUTICAL DESIGN (2010)
The role of proteomics in depression research
Daniel Martins-de-Souza et al.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2010)
Endophenotype: a conceptual analysis
K. S. Kendler et al.
MOLECULAR PSYCHIATRY (2010)
Biomarkers to Predict Antidepressant Response
Andrew F. Leuchter et al.
CURRENT PSYCHIATRY REPORTS (2010)
A Genomewide Association Study Points to Multiple Loci That Predict Antidepressant Drug Treatment Outcome in Depression
Marcus Ising et al.
ARCHIVES OF GENERAL PSYCHIATRY (2009)
Pharmacogenomics: The Promise of Personalized Medicine for CNS Disorders
Jose de Leon
NEUROPSYCHOPHARMACOLOGY (2009)
Selecting among second-step antidepressant medication monotherapies
A. John Rush et al.
ARCHIVES OF GENERAL PSYCHIATRY (2008)
The FKBP5-gene in depression and treatment response -: An association study in the sequenced treatment alternatives to relieve depression (STAR*D) cohort
Magnus Lekman et al.
BIOLOGICAL PSYCHIATRY (2008)
How can we realize the promise of personalized antidepressant medicines?
Florian Holsboer
NATURE REVIEWS NEUROSCIENCE (2008)
Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression
Manfred Uhr et al.
NEURON (2008)
Drug development for CNS disorders: strategies for balancing risk and reducing attrition
Menelas N. Pangalos et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression -: A potential biomarker?
Marcus Ising et al.
BIOLOGICAL PSYCHIATRY (2007)
Epigenetic regulation in psychiatric disorders
Nadia Tsankova et al.
NATURE REVIEWS NEUROSCIENCE (2007)
Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial
Sidney H. Kennedy et al.
AMERICAN JOURNAL OF PSYCHIATRY (2007)
Viewpoint -: How can drug discovery for psychiatric disorders be improved?
Yves Agid et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice
MH Trivedi et al.
AMERICAN JOURNAL OF PSYCHIATRY (2006)
Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment
EB Binder et al.
NATURE GENETICS (2004)
Micrornas: Small RNAs with a big role in gene regulation
L He et al.
NATURE REVIEWS GENETICS (2004)
Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption
M Uhr et al.
BIOLOGICAL PSYCHIATRY (2003)
Regional metabolic effects of fluoxetine in major depression: Serial changes and relationship to clinical response
HS Mayberg et al.
BIOLOGICAL PSYCHIATRY (2000)
Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to Mdr1a P-glycoprotein gene disruption
M Uhr et al.
NEUROPSYCHOPHARMACOLOGY (2000)
Share Paper
